All Stories

  1. What happens if you switch from originator to biosimilar therapy in JIA?
  2. Potential impact of European Medicines Agency measures to minimise risk of serious side effects on JAKi prescribing and utilisation in the UK
  3. Prognostic factors associated with failure of total elbow arthroplasty
  4. Comparative effectiveness of a second TNF inhibitor versus a non‐TNF biologic in the treatment of polyarticular course juvenile idiopathic arthritis
  5. Evaluation of discontinuation for adverse events of JAK inhibitors and bDMARDs in an international collaboration of rheumatoid arthritis registers (the ‘JAK-pot’ study)
  6. Evaluation of serious infections, including Mycobacterium tuberculosis, during treatment with biologic disease-modifying antirheumatic drugs: does line of therapy matter?
  7. Switching from the original etanercept to a biosimilar for RA: just as good as the originator.
  8. Impact of Risk Factors on COVID‐19 Outcomes in Unvaccinated People with Rheumatic Diseases
  9. Prognostic factors associated with failure of total elbow replacement: a protocol for a systematic review
  10. Socioeconomic deprivation is associated with reduced response and lower treatment persistence with TNF inhibitors in rheumatoid arthritis
  11. Starting a biologic for the first time – are biosimilars truly ‘similar’?
  12. Association Between Race/Ethnicity and COVID ‐19 Outcomes in Systemic Lupus Erythematosus ( SLE ) Patients from the United States: Data from the COVID ...
  13. Continuing specialist care into adulthood in young people with juvenile idiopathic arthritis: a retrospective cohort study using electronic health records in England
  14. If you stop biologic therapy for remission, are you likely to remain off treatment?
  15. Development and external validation of a model predicting new‐onset chronic uveitis at different disease durations in juvenile idiopathic arthritis
  16. Development of a Prediction Model for COVID ‐19 Acute Respiratory Distress Syndrome in Patients With Rheumatic Diseases: Results From the Global Rheumatology Alliance Registry
  17. Environmental and societal factors associated with COVID-19-related death in people with rheumatic disease: an observational study
  18. JAK-pot collaboration: comparing how well advanced therapies work in patients with RA
  19. Effectiveness of sequential biologic and targeted disease modifying anti-rheumatic drugs for rheumatoid arthritis
  20. Children and young people with arthritis are not at high risk of severe COVID-19.
  21. Characteristics associated with poor COVID-19 outcomes in individuals with systemic lupus erythematosus: data from the COVID-19 Global Rheumatology Alliance
  22. Safety of vaccination against SARS-CoV-2 in people with rheumatic and musculoskeletal diseases: results from the EULAR Coronavirus Vaccine (COVAX) physician-reported registry
  23. Outcomes of COVID-19 in patients with primary systemic vasculitis or polymyalgia rheumatica from the COVID-19 Global Rheumatology Alliance physician registry: a retrospective cohort study
  24. Children and young people with arthritis… What other diseases do they have?
  25. Associations of baseline use of biologic or targeted synthetic DMARDs with COVID-19 severity in rheumatoid arthritis: Results from the COVID-19 Global Rheumatology Alliance physician registry
  26. Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician-reported registry
  27. Understanding Refractory Rheumatoid Arthritis: Implications for a Therapeutic Approach
  28. Which biologic drugs are used, and how well do they work, in children and young people with JIA
  29. Risk of uveitis in patients with JIA receiving etanercept: challenges of analysing real-world data
  30. Cervical screening attendance and results for women with rheumatoid arthritis in England
  31. Moderate disease does not necessarily mean moderate disability
  32. Methotrexate remains an effective treatment for JIA, although nausea is common
  33. Use and effectiveness of rituximab in children and young people with JIA
  34. Improved disease activity in patients with systemic JIA treated with tocilizumab or anakinra
  35. Cancers and deaths in patients with severe psoriatic arthritis on TNF-inhibitor treatment.
  36. Identifying treatment refractory disease in people with rheumatoid arthritis
  37. Long-term rituximab treatment in patients with rheumatoid arthritis
  38. TNF inhibitors and dementia in patients with rheumatoid arthritis
  39. Long-term TNF-inhibitor treatment in patients with psoriatic arthritis
  40. How common is remission in juvenile idiopathic arthritis?
  41. Patterns of height growth in patients with juvenile idiopathic arthritis.
  42. Registries and cohort studies around the world in juvenile idiopathic arthritis.
  43. Effect of Rituximab on pregnancy outcome in women with Rheumatoid Arthritis
  44. Lupus and vasculitis‐like events in patients with rheumatoid arthritis treated with TNFi therapy
  45. Tocilizumab in patients with rheumatoid arthritis in the United Kingdom
  46. Mortality in juvenile idiopathic arthritis - increased in systemic juvenile idiopathic arthritis.
  47. Adults with Juvenile Idiopathic Arthritis on TNFi therapy in the United Kingdom.
  48. Cancer in patients with RA receiving TNF inhibitors or rituximab with prior malignancy
  49. Risk of pneumonia infection in patients with rheumatoid arthritis treated with TNFis
  50. Choice of biologics for children with juvenile idiopathic arthritis in the United Kingdom.
  51. One year of treatment with etanercept (Enbrel) in children with juvenile idiopathic arthritis
  52. Discovery of recent swine infectious agents.
  53. Infections in children with juvenile idiopathic arthritis treated with etanercept.
  54. Height change in children with juvenile idiopathic arthritis after two years of etanercept (Enbrel).
  55. Comparing patients with Rheumatoid Arthritis in European biologic registers
  56. Canine epilepsy in the UK - how common is it and which dogs are at risk?